CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days
The Indian Hotels Company Ltd. 24/08/2023401.85517.9007/02/2024 28.88% 167 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

Dnyanada Kulkarni
/ Categories: Trending, Markets

Overnight Digest: Stocks to look out for on October 16, 2018

The stocks most likely to witness significant movement on the bourses on October 16, 2018 are Pitti Engineering Solutions, Reliance Industrial Infrastructure Limited, Natco Pharma, Avenue Supermarts and Dr. Reddy’s Laboratories. 

Pitti Engineering Solutions: In a press release to NSE, the company reported its Q2FY19 financial results as follows – Total Income of Rs. 175.32 crore increased 108.44 per cent Y-o-Y, EBITDA of Rs. 25.95 crore posted a Y-o-Y growth of 110.46 per cent and total comprehensive income of Rs. 8.06 crore increased 107.73 per cent Y-o-Y. The stock is likely to be in the limelight in tomorrow’s trading session. 

Reliance Industrial Infrastructure Limited: RIIL posted a growth of 5.79 per cent in terms of total revenue which stood at Rs. 25.18 crore in Q2FY19 from Rs. 23.80 crore in Q2FY18. The stock will be watched tomorrow. 

Natco Pharma: The stock gained 6 per cent upon court’ affirmation invalidating the copaxone patents. The stock is likely to be in the limelight in tomorrow’s trading session. 

Avenue Supermarts: Although the company’s revenue rose 39 per cent to Rs. 4,872 crore in Q2FY19 from Rs. 3,507 crore in Q2FY18, the stock price dropped 6 per cent in today’s trading session. The stock will be monitored tomorrow. 

Dr. Reddy’s Laboratories: The company has entered into a definitive agreement for the sale of its active pharmaceutical ingredients (APIs) manufacturing business unit in Hyderabad to Therapiva Private Limited. The stock is likely to be in action in tomorrow’s trading session. 


Previous Article Lupin receives tentative USFDA approval, stock tops Nifty pharma
Next Article Indiabulls Housing Finance net profit grows by 21.25 per cent in Q2FY19
Print
3220 Rate this article:
3.9
Please login or register to post comments.

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR